Quest Diagnostics Announces Increased Dividend and Share Repurchase Authorization

The Board of Directors at Quest Diagnostics has approved a 7.5% increase in its quarterly cash dividend, raising it from $0.80 to $0.86 per share. This decision underscores the company’s dedication to returning value to its shareholders, marking the 15th consecutive year of dividend increases.

The new dividend rate will be effective for the upcoming payment scheduled for April 20, 2026. Shareholders on record as of April 6, 2026, will benefit from this increased dividend, which translates to an annual cash dividend of $3.44 per share. Such a sustained commitment to dividend growth not only reflects robust financial health but also enhances the attractiveness of Quest Diagnostics as a long-term investment opportunity.

In addition to the dividend increase, Quest Diagnostics announced a substantial $1 billion increase in its share repurchase authorization. This decision is significant, building upon approximately $0.4 billion that was already available under the company’s existing share repurchase program as of December 31, 2025.

The increased share repurchase authorization demonstrates the company’s confidence in its financial position and future growth prospects. By repurchasing shares, Quest Diagnostics aims to reduce the number of shares outstanding, potentially increasing the value of remaining shares and providing an immediate return on investment for shareholders.

Quest Diagnostics emphasizes its mission to connect individuals with vital laboratory insights, aiming to enhance health management across the healthcare landscape. With an extensive network serving half of the physicians and hospitals in the United States, the company plays a crucial role in informing healthcare decisions for one in three American adults each year.

Employing nearly 57,000 staff members, Quest Diagnostics continues to innovate in the field of diagnostic testing, focusing on smarter and simpler approaches to healthcare. The latest financial maneuvers are indicative not just of a strong fiscal strategy but also of a broader commitment to improving health outcomes through insightful diagnostics.

The recent announcements from Quest Diagnostics regarding its dividend increase and enhanced share repurchase authorization signal a strong financial outlook and a commitment to shareholder value. As the company continues to thrive in the competitive healthcare landscape, these financial strategies will likely bolster its standing among investors and reinforce its role as a leader in diagnostic services.